Stocks to watch on brokerages today, July 1: Polycab, Apollo Hospitals, Reliance Industries, Dixon Technologies and more
Leading global brokerages have updated their views on key Indian stocks as of July 1, adjusting their ratings and target prices in response to recent developments and business performance. Here's a summary of the latest brokerage actions: Polycab : Jefferies has maintained its 'Buy' rating with a target price of ₹7,150 per share.
Apollo Hospitals : Citi has reiterated its 'Buy' call with a target of ₹8,260, while Morgan Stanley has maintained an 'Overweight' rating with a target price of ₹8,058.
DLF : CLSA continues to rate the stock as 'Outperform' with a price target of ₹1,025.
Reliance Industries : Nuvama has reaffirmed its 'Buy' rating with a target price of ₹1,801.
Torrent Pharmaceuticals : Bank of America has maintained a 'Neutral' view and raised the target price to ₹3,500.
Ambuja Cements : Jefferies has kept a 'Buy' rating intact with a price target of ₹700.
OnsSource : DAM has initiated coverage with a 'Buy' call and a price target of ₹2,529.
Asian Paints : ICICI Securities has upgraded its rating to 'Add' and revised the target price to ₹2,700.
Berger Paints : ICICI Securities has also upgraded the stock to 'Add' with a higher target of ₹650.
ACC : CLSA has commented on the company's focus on achieving its capacity expansion goal of 140 million tonnes by FY28.
Dixon Technologies: Morgan Stanley has downgraded the stock to 'Underweight' with a revised target price of ₹11,563.
Disclaimer: The views and recommendations expressed above are those of the respective brokerage firms. They do not represent the views of this publication and are not investment advice. Investors are advised to consult with certified financial advisors before making any investment decisions.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.
When a U.S. president threatens your industry with a 200% tariff, that's not typically good news. But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, investors have been cautiously celebrating. Despite a broad stock selloff on Friday, the NYSE Arca Pharmaceutical Index is up around 1% over the past week, compared with a basically flat performance for the S&P 500. Inside the Shadowy, Lucrative Business of 'Superfake' Luxury Handbags SpaceX to Invest $2 Billion Into Elon Musk's xAI The Best EV Deals Now Are on the Used Market That outperformance may seem puzzling, but for Wall Street, the size of the tariff matters less than the timing. The 200% figure lit up cable news chyrons, but investors focused instead on the grace period Trump floated. 'We're going to give people about a year, year and a half to come in, and after that, they're going to be tariffed,' he said. A year and a half is a long runway—and it could turn out to be even longer in practice. In a note titled 'Tariffs Schmariffs,' Jefferies analyst Akash Tewari argues that if the grace period begins some time this year and lasts for a year and a half, companies could continue importing drugs tariff-free until 2027. They could buy even more time if they stockpile during that period to cover demand at least until some time in 2028. That might give them time to build entirely new U.S. manufacturing facilities, which typically takes around four years. This doesn't mean Trump isn't getting what he wants. After all, the tariffs are meant as a threat to push companies to make more of their products in the U.S. And in this case, the threat seems to be working. Since Trump began threatening pharma with tariffs, the industry has moved on two fronts. First, companies have been stockpiling drugs at a furious pace to build a cushion. For instance, the Wall Street Journal reported last month that $36 billion worth of hormone treatments—used in popular obesity and diabetes drugs—have been shipped from Ireland this year, more than double last year's total. Second, the industry has announced major investments in U.S. manufacturing. Some of that may be political posturing, but much of it reflects a real shift. Companies increasingly see no choice but to bring production back, at least for drugs sold to American patients. Eli Lilly, for example, has announced a $27 billion plan to expand manufacturing in the U.S. Making drugs in the U.S.—and registering the intellectual property here—comes with a tax hit. That is a big reason the industry offshored production to low-tax countries like Ireland in the first place. But Trump's 'Big Beautiful Bill' offers some relief to offset the pain. The bill lets companies immediately deduct R&D expenses and equipment purchases and raises the cap on how much interest they can write off—making it a lot cheaper to build new plants at home. The upshot: with more time to prepare and a friendlier tax environment, pharma companies may barely feel the sting of tariffs. Take Merck. The company plans to produce a new version of its blockbuster drug Keytruda in the U.S. Jefferies estimates that with steps like stockpiling, gradually shifting production and trimming some costs, the hit to Merck's earnings from tariffs in 2027 and 2028 could be just 1% to 2%. That is actually better than Jefferies's earlier model for a smaller 25% tariff, which assumed fewer workarounds. The sense of a new normal settling in around Trump's second presidency might help explain why dealmaking has returned to the sector. Merck this past week announced a roughly $10 billion deal to buy Verona Pharma. That followed a series of other deal announcements, including Eli Lilly's $1.3 billion pact to acquire Verve Therapeutics. By the end of Trump's term, the U.S. pharmaceutical supply chain could look very different, with a greater share of innovative drug production happening on American soil. That would be a rare win-win—for the White House and for the industry. Write to David Wainer at Economists See Lower Recession Risk and Stronger Job Growth: WSJ Survey Can Pittsburgh's Old Steel Mills Be Turned Into an AI Hub? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Morgan Stanley Exec on the IPO Market and Robinhood's Tokenized Stocks
Arnaud Blanchard, global head of equity capital markets at Morgan Stanley, joins WSJ's Take On the Week to discuss how recent IPO deals from companies like Chime and Voyager Technologies are helping the IPO market get a mild bump, where the market is expected to go in the second half of 2025, and if there is any potential of the market returning to 2021 highs. Sign in to access your portfolio
CNBC
3 hours ago
- CNBC
Tesla supplier CATL has potential beyond just batteries, analysts say
For Tesla supplier Contemporary Amperex Technology , selling battery packs to major electric companies is just the start of its ambitions. "We believe the company is not just a hardware manufacturer, but it will also be a software ecosystem provider," Morgan Stanley analysts led by Jack Lu said in a report Wednesday. They pointed to CATL's artificial intelligence-powered tools for monitoring batteries on the road and giving early safety warnings. "As AI develops, the ecosystem will likely further evolve and provide more value added soft services to customers," the Morgan Stanley analysts said, noting that improved safety will also strengthen CATL's business partnerships and competitiveness. Morgan Stanley raised its price target on CATL's Hong Kong-listed shares to 445 Hong Kong dollars ($56.69), up 14% from 390 HKD previously. The new price target is nearly 18% above where CATL closed Friday, after reaching an intraday high of 395 HKD on Thursday. That was the highest since CATL shares listed in Hong Kong on May 20 in the world's biggest IPO of 2025. The company's mainland-listed shares have traded at an abnormally large discount to the Hong Kong shares. CATL also looks to be a step closer to generating revenue from licensing. Ford agreement U.S. automaker Ford has planned to open a battery factory through a licensing agreement with CATL. But the deal came under intense U.S. scrutiny , while there were concerns that Ford would lose advanced manufacturing tax credits. But Ford in the last week said it expects its BlueOval Battery Park in Michigan will benefit from such tax credits, and " remains on track to begin production of lithium iron phosphate (LFP) batteries in 2026." While the release did not mention CATL, analysts were hopeful. "This recent news is positive in that it appears there is tacit acceptance of the licensing arrangement," Macquarie analysts Eugene Hsiao and Fergus Kwan said in a report Wednesday, noting the development "helps to remove one key headwind on the shares." Neither CATL nor Ford immediately responded to a CNBC request for comment. CATL could receive 1.3 billion yuan ($181 million) in annual licensing fees if BlueOval operates near full capacity by 2027, although the battery company's profits won't likely benefit until then, the Macquarie analysts said. They have a price target of 360 HKD on CATL shares. U.S. scrutiny But CATL remains under broader scrutiny in the U.S. Earlier this year, the Pentagon added CATL to a "Chinese military" list that prohibits the U.S. Department of Defense from buying the company's products starting in 2026. CATL at the time said the designation was "a mistake" and that it "is not engaged in any military-related activities." "We believe geopolitical risk between China and the U.S. is already priced into the shares," the Macquarie analysts said. "Strong earnings fundamentals from market share gains in Europe, coinciding with increased shareholder returns, should lead to a valuation re-rating." CATL has pledged 90% of the funds raised by going public would support its expansion into Europe , especially a factory in Hungary that's nearing completion. The company last month also said a subsidiary has reached a deal in Indonesia for a $6 billion project that aims to cover nickel mining and processing, battery production and battery recycling. "We maintain our Buy rating for CATL," Bank of America analysts led by Ming Hsun Lee said in a July 2 report, "given its industry-leading battery technology and new product strategy to protect its market share, as well as its edge in technology and scale to drive more room for cost savings and sustained high" gross profit margins. The analysts have a 400 HKD price target on the stock. They highlighted that, in CATL's main line of business, Xiaomi will use the CATL's battery in its popular YU7 SUV, "which should be positive to CATL's [market] share in China." CATL has also built business partnerships in new technologies around battery swapping and packs designed specifically for hybrid-powered cars . Geely -backed electric car company Zeekr on Wednesday announced its hybrid driving system is based on CATL's "Freevoy Super Hybrid Battery." The technology will be used in Zeekr's first hybrid vehicle, the 9X SUV, which has a range of 380 kilometers on a single charge and is set to begin deliveries in China by the end of September, a statement said. — CNBC's Michael Bloom contributed to this report.
